Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic biosimilarity of Epostim vs Eprex in chronic haemodialysis patients with anaemia due to ESRD
2006-004929-28Phase 2Terminated
- Sponsor
- GeneMedix plc
- Start
- Jun 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of epostim in Uraemic Anaemia and end-stage kidney disease (ESKD) (2 arms), sponsored by GeneMedix plc. Primary endpoint: Therapeutic efficacy comparability. Started Jun 2008; status: terminated.
02
Drugs
epostim
03
Conditions
Uraemic Anaemiaend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2006-004929-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004929-28.